Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.62 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.50 |
| ▸ | CLK2 | P49760 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.50 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | SGK2 | Q9HBY8 | 2/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13483442 | 0.86 | ALDH1A1 (0.62) | MAPK1DYRK1ARAB9ANOS1ALDH1A1 | |
| SCHEMBL27989422 | 0.80 | ROCK2 (0.52) | ROCK2ROCK1MAPK1CSNK2A1PRKD3 | |
| SCHEMBL2569041 | 0.80 | ROCK2 (0.63) | ROCK2ROCK1MAPK1CSNK2A1PRKD3 | |
| SCHEMBL21348752 | 0.79 | ROCK2 (0.43) | ROCK2ROCK1MAPK1CSNK2A1PRKD3 | |
| SCHEMBL17210583 | 0.79 | KCNH3 (0.62) | ROCK2ROCK1POLBCDC7RAB9A | |
| SCHEMBL5414929 | 0.79 | ROCK2 (0.56) | ROCK2ROCK1MAPK1PRKD3MAP4K4 | |
| SCHEMBL13122244 | 0.79 | ROCK2 (0.54) | ROCK2ROCK1MAPK1PIM1CDK2 | |
| SCHEMBL2565558 | 0.77 | ROCK2 (1.00) | ROCK2ROCK1MAPK1CSNK2A1PRKD3 | |
| SCHEMBL20905260 | 0.77 | ROCK2 (0.58) | ROCK2ROCK1MAPK1CSNK2A1PRKD3 | |
| SCHEMBL5564049 | 0.77 | MKNK1 (0.60) | ROCK2ROCK1MAPK1CSNK2A1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-20220081402-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-03-17 | — | — | US | disclosed |
| US-11230535-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200181097-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-06-11 | — | — | US | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081402-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | ROCK2 2702/4885ROCK1 3065/4885MAPK1 3851/4885 |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | ROCK2 4711/4885ROCK1 4593/4885MAPK1 2655/4885 |
| US-11230535-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | ROCK2 2702/4885ROCK1 3065/4885MAPK1 3851/4885 |
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885MAPK1 27/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | ROCK2 4624/4885ROCK1 4476/4885MAPK1 3243/4885 |
| US-20200181097-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | ROCK2 2702/4885ROCK1 3065/4885MAPK1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.